期刊
CURRENT CANCER DRUG TARGETS
卷 18, 期 2, 页码 177-187出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568009617666170222125035
关键词
Cancer gene therapy; measles virus clinical trials; MV-CEA; MV-NIS; oncolytic measles; virotherapy
类别
资金
- National Institutes of Health [T32 CA009666]
- NIH [P50 CA108961, P50 CA 116201, P50 CA 136393, R01 CA 154348, R01 136547]
- NATIONAL CANCER INSTITUTE [R01CA136547, R01CA154348, P50CA108961, P50CA186781, P50CA116201, R01CA200507, P50CA136393, T32CA009666] Funding Source: NIH RePORTER
Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据